vs

Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $93.1M, roughly 1.6× HIVE Digital Technologies Ltd.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -98.1%, a 92.6% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 128.4%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 102.2%).

Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

HIVE vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.6× larger
TARS
$151.7M
$93.1M
HIVE
Growing faster (revenue YoY)
HIVE
HIVE
+90.2% gap
HIVE
218.6%
128.4%
TARS
Higher net margin
TARS
TARS
92.6% more per $
TARS
-5.5%
-98.1%
HIVE
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
102.2%
HIVE

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
HIVE
HIVE
TARS
TARS
Revenue
$93.1M
$151.7M
Net Profit
$-91.3M
$-8.4M
Gross Margin
-27.1%
Operating Margin
-5.3%
Net Margin
-98.1%
-5.5%
Revenue YoY
218.6%
128.4%
Net Profit YoY
-234.0%
63.8%
EPS (diluted)
$-0.38
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIVE
HIVE
TARS
TARS
Q4 25
$93.1M
$151.7M
Q3 25
$87.3M
$118.7M
Q2 25
$45.6M
$102.7M
Q1 25
$78.3M
Q4 24
$29.2M
$66.4M
Q3 24
$22.6M
$48.1M
Q2 24
$32.2M
$40.8M
Q1 24
$27.6M
Net Profit
HIVE
HIVE
TARS
TARS
Q4 25
$-91.3M
$-8.4M
Q3 25
$-15.8M
$-12.6M
Q2 25
$35.0M
$-20.3M
Q1 25
$-25.1M
Q4 24
$68.2M
$-23.1M
Q3 24
$80.0K
$-23.4M
Q2 24
$-18.3M
$-33.3M
Q1 24
$-35.7M
Gross Margin
HIVE
HIVE
TARS
TARS
Q4 25
-27.1%
Q3 25
4.7%
Q2 25
-13.6%
Q1 25
Q4 24
-43.7%
Q3 24
-66.1%
Q2 24
-7.4%
Q1 24
Operating Margin
HIVE
HIVE
TARS
TARS
Q4 25
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
HIVE
HIVE
TARS
TARS
Q4 25
-98.1%
-5.5%
Q3 25
-18.1%
-10.6%
Q2 25
76.8%
-19.8%
Q1 25
-32.1%
Q4 24
233.2%
-34.8%
Q3 24
0.4%
-48.7%
Q2 24
-56.7%
-81.6%
Q1 24
-129.4%
EPS (diluted)
HIVE
HIVE
TARS
TARS
Q4 25
$-0.38
$-0.17
Q3 25
$-0.07
$-0.30
Q2 25
$0.18
$-0.48
Q1 25
$-0.64
Q4 24
$0.52
$-0.57
Q3 24
$0.00
$-0.61
Q2 24
$-0.17
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIVE
HIVE
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$559.3M
$343.4M
Total Assets
$624.0M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIVE
HIVE
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$40.5M
$291.4M
Q3 24
$31.7M
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
HIVE
HIVE
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
HIVE
HIVE
TARS
TARS
Q4 25
$559.3M
$343.4M
Q3 25
$624.6M
$335.1M
Q2 25
$560.5M
$332.6M
Q1 25
$342.5M
Q4 24
$430.9M
$224.5M
Q3 24
$275.5M
$237.5M
Q2 24
$268.6M
$252.2M
Q1 24
$275.2M
Total Assets
HIVE
HIVE
TARS
TARS
Q4 25
$624.0M
$562.2M
Q3 25
$693.0M
$534.6M
Q2 25
$628.7M
$495.0M
Q1 25
$500.8M
Q4 24
$478.6M
$377.0M
Q3 24
$334.7M
$376.3M
Q2 24
$376.8M
Q1 24
$349.3M
Debt / Equity
HIVE
HIVE
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIVE
HIVE
TARS
TARS
Operating Cash FlowLast quarter
$46.0M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIVE
HIVE
TARS
TARS
Q4 25
$46.0M
$19.3M
Q3 25
$-10.6M
$18.3M
Q2 25
$10.2M
$-29.4M
Q1 25
$-20.7M
Q4 24
$-28.5M
$-22.2M
Q3 24
$-2.2M
$-8.7M
Q2 24
$-4.4M
$-14.4M
Q1 24
$-37.8M
Free Cash Flow
HIVE
HIVE
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-55.5M
$-22.3M
Q3 24
$-34.7M
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
HIVE
HIVE
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-189.9%
-33.5%
Q3 24
-153.4%
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
HIVE
HIVE
TARS
TARS
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
92.5%
0.1%
Q3 24
143.9%
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
HIVE
HIVE
TARS
TARS
Q4 25
Q3 25
Q2 25
0.29×
Q1 25
Q4 24
-0.42×
Q3 24
-26.94×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons